Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase EARLY_PHASE1 2Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 19Colorectal Neoplasms 19Recurrence 17Pancreatic Neoplasms 17Multiple Myeloma 15Advanced Solid Tumors 13Prostatic Neoplasms 12Advanced Solid Tumor 12Stomach Neoplasms 10Ovarian Neoplasms 10Leukemia, Myeloid, Acute 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 8Neoplasm Metastasis 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Lymphoma, Large B-Cell, Diffuse 6Head and Neck Neoplasms 6Glioblastoma 6Urinary Bladder Neoplasms 5Solid Tumors 5Solid Tumor 5Lymphoma, B-Cell 5Lung Neoplasms 5Liver Neoplasms 5Glioma 5Endometrial Neoplasms 5

Interventions

resiniferatoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Cancer Pain × Clear all
NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡